Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protectival is a clinically researched botanical formulation developed by LifeBiotic, based on the LCS101 complex. It is designed for oncology supportive care to mitigate the side effects of conventional cancer treatments like chemotherapy and radiation. The formula is composed of extracts from 10 specific herbs, including *Astragalus membranaceus*, *Poria cocos*, and *Atractylodes macrocephala*. It functions through multi-pathway immune modulation, supporting healthy white and red blood cell levels, promoting cellular resilience, and improving the quality of life for patients undergoing oncology treatments. Clinical studies, including randomized controlled trials, have suggested its role in reducing hematological toxicity (such as anemia and neutropenia) and enhancing immune function without interfering with the efficacy of chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Protectival.